U.S. Markets open in 6 hrs 35 mins

Northwest Biotherapeutics, Inc. (NWBO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.29000.0000 (0.00%)
At close: 3:59PM EDT
Sign in to post a message.
  • J
    Joey Angels
    …. Why is she distancing herself slowly but gracefully from the study?
    Looks like they made LL's video private. Indeed, the rock and the hard place do not result from the impossibility of designing a new trial, but from the impossibility of salvaging one where the trial design leaves something to be desired. When the trial was started back in 2006, the PPS was around $100/share, and the company could have raised the needed funds to do a large trial (or two or three) in a compressed time-frame. Why that didn't happen remains a mystery.
  • R
    Ronnie
    Practice runs “may” begin during the summer, summers over. Looks as this was composed again to deceive shareholders and kick the ball down the road so the scam artist could dump .01 cent options and convert .25 penny warrants.

    “The next step will be an on-site inspection of the facility by MHRA. Following the inspection, a report of the inspection results and any findings needing any corrective action will be issued by MHRA. Following completion of any actions, the Company is hopeful that an initial license will be issued and production of GMP DCVax-L products in the Sawston facility may begin by around the end of Q3.

    In addition to the MHRA submission activities, a prototype of the Flaskworks system has been delivered to the Sawston facility, and the Company currently anticipates that initial practice runs with the system may begin at the Sawston facility during the summer”.
  • L
    LearningCurve2020
    Hubber's quickly removed this one:

    The truth; They don't need to sell the story with people here doing it for them 24/7.

    Before NWBO what'd Powers do with all that cash going into her stem cell and other picks? All to the ether.

    Why are three ex government officials and three ex Intel community pros involved in this tiny biotech located so close to DC instead of Seattle?...

    And, why does the SEC treat them with kid gloves even after all these years?
  • L
    LearningCurve2020
    An oldie but a goodie from 2014. Forgot all about this one. This puts to rest the Hubber pretense that Woodford was the bad guy. It's not how one takes over a company. In fact, Woodford shined a $$light on NWBO and was repaid with...well, you know.

    'Woodford's new biotech could be the next Amgen'

    The boss of Northwest Biotherapeutics (NWBO.O), the US cancer drug specialist that is the latest investment by fund manager Neil Woodford, believes the firm could become the next biotech colossus if medical trials of its products go well.
  • J
    Joey Angels
    Not one trial involving this scam at the Mayo Clinic.
    Not one clinical trial at the Mayo Clinic
    https://www.mayoclinic.org/departments-centers/brain-tumor-program/sections/clinical-trials/rsc-20439939
  • L
    LearningCurve2020
    2006
    Toucan currently has investments in 10 stem cell companies, including more than $60 million in Maryland-based firms.
  • B
    Bruce
    It's a new day, just received great news from a friend whose father had brain cancer, three tumors 10 Months ago. His father would not be able to survive traditional SOC, chemo. However, his father qualified for immunotherapeutic and biotherapeutic treatment which was linked to NWBO. As of two weeks ago, all of the brain cancer is gone completely, praise God. NWBO is one of the leaders in immunotherapeutic and biotherapeutic treatments, and we know that DCVax works. This is a fact, and there anyone with a brain would understand that NWBO is on the verge of a great victory in the treatment for brain cancer and other cancers, Hence, why would anyone bash and also short NWBO, it is obvious so no need to go down this path. Wake up people and smell the coffee, immunotherapeutic and biotherapeutics is on the threshold to help cure many cancer patients. The writing is on the wall regarding NWBO, DCVax works, many people with cancer will reap the benefits from DCVax, and NWBO will in fact indicate positive revenue growth. All of these factors will support a higher value for NWBO. The great news, during this quit period, NWBO indicated that their focus was on their next development phase which they indicated as their manufacturing process. Since early this year, NWBO has established working relationships with multiple manufacturing facilities. NWBO has indicated that their manufacturing process would be complete near the end of the third quarter, Q3, September this year. Detailed discussions with several pharmaceutical sales people support the fact that if your products are effective, you remain quiet until you have a substantial manufacturing capability on hand, and the produce is ready to deploy. Here we are, closing in of the end of September, there is a high probability that we will hear great news from NWBO. All of these factors indicate a positive path forward for NWBO, and a worthy investment indeed.
    Bullish
  • J
    Joey Angels
    and still Sept. 2021 says… Many institutions and funds such as Blackrock, Vanguard, Statestreet etc. have microcsp divisions and even invest in companies less than 1 pps. They can spot this scam a mile away.
    https://www.nasdaq.com/market-activity/stocks/nwbo/institutional-holdings
    Interesting 18 full time employees and not one has bought a single share on the open market. Not even Linda F.. Ponz”s is chauffeur.
    https://www.nasdaq.com/market-activity/stocks/nwbo/insider-activity
  • M
    Mary
    Xonixt359, “a”, Jean, Matt, MichaelK & N, Keith & Katerina the walls are closing in. With that have a nice evening.
  • J
    Joey Angels
    Sept. 2021 says… Many institutions and funds such as Blackrock, Vanguard, Statestreet etc. have microcsp divisions and even invest in companies less than 1 pps. They can spot this scam a mile away.
    https://www.nasdaq.com/market-activity/stocks/nwbo/institutional-holdings
    Interesting 18 full time employees and not one has bought a single share on the open market. Not even Linda F.. Ponz”s is chauffeur.
    https://www.nasdaq.com/market-activity/stocks/nwbo/insider-activity
  • L
    LearningCurve2020
    Boom! A DCVAX trial redux or more completion? Pass this on to H'ers:

    In live trials, Davi expects the FDA to be more receptive, at least initially, to a hybrid model, in which the external controls supplement, rather than replace, a standard control arm. Medidata Acorn AI recently helped a customer design a hybrid control arm for a Phase 3 trial — usually the final trial before the FDA approves a drug for general use — for a treatment for recurrent glioblastoma,

    https://www.medidata.com/en/life-science-resources/medidata-blog/fda-and-external-control-arms
  • J
    Joey Angels
    …. And we return to 2021…. Northwest Biotherapeutics
    Northwest Biotherapeutics is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more "audacious" than that of the previous companies.

    The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company "phase-shifted" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.

    The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that "no interim analysis of efficacy in the Phase III trial [had] been done." What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.

    The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.
  • M
    Mary
    ….. Lucy as Linda F. Ponzi and 19 years with waiting Charlie Shareholder Brown. Another conference Charlie, wait until Oct…
  • J
    Joey
    Back up the truck on this one before it’s hammer time here.
    https://finance.yahoo.com/quote/LCID/
  • J
    Jake
    I have to say, this whole NWBO thing is one hell of a scam. In so many regards it has been played really, really well. In the end, I hope to know all the details of how they pulled the whole thing off, right down to the transcripts of phone calls and emails posted in iHub and elsewhere. I'll bet it's a fascinating story. Phase V didn't even scratch the surface of what is going on here.
  • R
    RichardUpward
    $NWBO short interest sitting at the lowest level in well over a year. Warrant/option holders are diluting retail investors on an almost daily basis. Best wishes.
    Bearish
  • L
    LearningCurve2020
    Poorman stepping out of line over there by pointing out what's so obvious. The Hubber confusion police moving in on him.

    Pierce that corporate veil!
  • R
    RichardUpward
    It's well past time $NWBO puts this stale PIII trial to bed. Over the last 15+ years, advancements in surgical procedures alone have obscured and made mute much of the ancient data regarding this almost two-decade-long relatively small, cherry-picked population. Best wishes
    Bearish
  • P
    Phil
    Looks like a very calculated disposition of shares almost daily with a few head fakes thrown in to attract retail buyers. Someone is cashing out.
  • J
    Jake
    Data on a Phase 3 trial speaks for itself. There is no way around it. You've either got the goods or you don't, like in NWBO's case and no amount of spin by them is going to change the facts.

    The scientific community (and ultimately the market) is going to see right through the spin. That's why 99 percent of these biotechs release TLD without a need for a simultaneous explanatory (spin) paper.

    This whole thing is a scam, and no company with really good data would go about releasing it this way. Only a company that needs to create a false narrative about the data would go about releasing it this way. You know it, I know it, and everybody else knows it. Because data speaks for itself.